Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab with or without daratumumab versus daratumumab + pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
NL-OMON53825Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Elranatamab monotherapy, Elranatamab + daratumumab and Daratumumab + pomalidomide + dexamethasone (3 arms). Primary endpoints: Dose-limiting toxicities, Progression-free survival and 2 more. Started Nov 2022; status: recruiting.
02
Drugs
elranatamabdaratumumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON53825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53825.